Trials of best supportive care vs. chemotherapy in front-line therapy of non-small-cell lung cancer
Multiple trials were completed in the 1980s to evaluate the efficacy of platinum-based chemotherapy vs. the best supportive care in non-small-cell lung cancer. Perhaps the most pivotal of these was by Rapp et al. from the National Cancer Institute of Canada, in which they demonstrated that platinum-based chemotherapy preferred a survival advantage of between 12 to 14 weeks over best supportive care with the one-year survival rate improving from 12% to 14% with best supportive care to approximately 24% to 26% with platinum-based chemotherapy [4] [5] [6] .
Novel agents in non-small-cell lung cancer reach the clinical forum
A variety of different novel agents have been tested in clinical trials in the 1990s. Most extensively tested have been the two taxanes, paclitaxel and docetaxel, the nucleotide analogue, gemcitabine [7] , and the novel vinca alkaloid, vinorelbine. While all of these agents have been tested vs. best supportive care in trials, largely carried out in Europe, only docetaxel [8] paclitaxel [9] and vinorelbine [10] have demonstrated a meaningful survival advantage when compared in randomized trials vs. best supportive care. The efficacy of gemcitabine was relatively transient and did not result in significant differences in median or one-year survival rates vs. best supportive care [11] .
Interestingly, Roszkowski [8] demonstrated in a randomized trial of 207 patients that treatment with docetaxel brought about a 25% one-year survival rate vs. a rate of 16% in the best supportive care arm. Overall survival times were 6 months vs. 5.7 months (P -0.026). Twelve percent of the patients treated with docetaxel were alive at two years, but none of 70 patients treated on the best supportive care arm were alive at 20 months. Interestingly, the difference is more striking when one censors the data from the 16% of patients on the best supportive care arm who are treated with off-protocol chemotherapy.
A phase III trial of paclitaxel vs. best supportive care of 157 patients included patients with stage I lib or IV NSCLC who had received no prior chemotherapy. All patients were randomized to either best supportive care alone (78 patients) or paclitaxel and best supportive care (79 patients). On this study, patients who received paclitaxel had a median survival advantage of two months (6.8 months) for paclitaxel vs. 4.8 months for patients who received best supportive care (P = 0.037). While quality of life was similar on both treatment arms, the functional activity score of the Rotterdam Symptom Checklist statistically significantly favored the paclitaxel plus best supportive care arm (two-sided P = 0.043). Disease progression was also dramatically better for paclitaxel vs. best supportive care (4.0 months vs. 1.2 months, P-0.0001).
However, all of these agents in combination with cisplatin have yielded measurable survival advantages over cisplatin alone, and multiple new combinations have been approved in the 1990s that have incrementally [12] . This article described a better survival rate for the combination of cisplatin and paclitaxel vs. cisplatin and etoposide. Because the toxic effects were less severe and there was no significant response differential between the two paclitaxel arms, the lower dose of paclitaxel (135 mg/m 2 over 24 hours) was preferred to the higher dose (250 mg/m 2 over 24 hours) ( Table 1) .
Similarly randomized trials by LeChevalier et al. and Wozniak et al. [13, 14] both demonstrated that cisplatin plus vinorelbine was superior not only to the combination of cisplatin with an older vinca alkoloid (velban) but also to cisplatin alone; statistically significant differences in both median and one-year survival rates were observed ( Table 1) .
The regimens of paclitaxel (250 mg/m 2 over three hours) and carboplatin (to an area under the curve of six) were compared in a randomized trial with vinorelbine (25 mg/m 2 weekly) and cisplatin (100 mg/m 2 every four weeks). This randomized trial conducted by the Southwest Oncology Group demonstrated no difference in response rate (both 27%) or in median survival time (both eight months). The one-year survival rate was also similar between the two arms (33% for cisplatin and vinorelbine vs. 34.5% for paclitaxel and carboplatin; P = ns). However, paclitaxel and carboplatin appeared to be better tolerated. About 30% of patients discontinued cisplatin and vinorelbine because of side effects, but only 13% of patients halted paclitaxel and carboplatin for that reason. However, given the nearly equal survival rates in terms of median and one-year estimations and the higher cost of the paclitaxel and carboplatin regimen, the investigators and others concluded that both regimens were approximately equally acceptable [15] (Table 1) .
Gemcitabine was also approved in combination with cisplatin as a front-line regimen for non-small-cell lung cancer. When gemcitabine at 1,000 mg/m 2 weekly, days 1, 8, 15 was added to cisplatin at 100 mg/m 2 and compared with a control arm of cisplatin alone by Sandier et al. [16] , the median survival rate was superior for the 262 patients who received the combination of gemcitabine and cisplatin (8.8 months; one-year survival rate = 37%) vs. that of those who received cisplatin alone (median survival time, of 7.4 months; 26% oneyear survival rate). Therefore, gemcitabine and cisplatin also represents an acceptable front-line combination for non-small-cell lung cancer (Table 1) .
Docetaxel has demonstrated extensive activity in phase II studies across several continents. Pooled data from 320 patients in which docetaxel was used as a front-line regimen indicate that it engendered an overall response rate of 31%, an intent-to-treat response rate of 27% and a median survival of 9.2 months [17] . In fact, response data [18] to date with docetaxel in combination with carboplatin or cisplatin do not indicate substantially better median or one-year survival with these combinations vs. data from phase II studies of docetaxel alone. Nevertheless, a randomized trial of docetaxel, with either cisplatin or carboplatin vs. vinorelbine and cisplatin recently closed to accrual, and the final results are expected to be announced shortly (Fossella F, Belani C, personal communications, 2000) .
In an attempt to determine which of the 'newer' platinum-based regimens is more effective in treating advanced NSCLC, the ECOG group conducted a phase III trial of over 1200 chemotherapy-naive patients with advanced NSCLC who were randomized to treatment with a reference regimen of cisplatin/paclitaxel vs. one of three comparator regimens: cisplatin/gemcitabine, cisplatin/docetaxel, or carboplatin/paclitaxel. The results of this trial were recently reported by Schiller [19] . This trial did not demonstrate a clear superiority of any of the regimens studied. Although the median timeto-progression favored treatment with cisplatin/gemcitabine (4.5 vs. 3.5 months for the reference regimen), there was no difference in the primary endpoint of survival between the four treatment groups. Other study end-points of median, one-year, and two-year survivals were similarly equivalent across the four groups, and averaged eight months, 33% and 12%, respectively. Nor was there any significant difference in objective response rates between the four arms, with an overall partial response rate of 18.6%. This trial did demonstrate that patients with performance status of 0 and 1 fared better than those with performance status of 2 with regard to toxicity and survival.
There were differences noted in side effects between the four groups. Specifically, patients in the cisplatin/ gemcitabine group experienced more renal toxicity and a higher incidence of toxicity-related treatment discontinuation, those in the cisplatin/docetaxel arm had more hypersensitivity reactions, and patients treated with paclitaxel experienced more neuropathy.
One criticism of this trial is that a benefit in overall survival might not have been seen because many patients presumably crossed over to second-line therapy upon disease progression. This may have, in effect, resulted in many patients essentially receiving the same therapy, thereby 'diluting' any possible benefit of one regimen over another. Because details about second-line therapy were not recorded in the study, this will remain an unanswered question. But certainly now that the survival advantage of second-line therapy with docetaxel has been demonstrated, any future trials of this type must designed to correct for the impact of second-line therapy.
Since none of the treatment arms demonstrated a clear superiority with regard to the primary study endpoint of survival, clinicians may base their decision of which regimen to use on factors such as expected side effects, patient convenience, expected impact on quality of life, and cost.
The question of whether cisplatin is absolutely essential in combination chemotherapy for stage IIIB-IV non-small-cell lung cancer was raised in a recent phase IIB trial by Georgoulias et al. in which 373 patients were randomized to receive treatment with either docetaxel and cisplatin or docetaxel and gemcitabine. Docetaxel was administered at 100 mg/m 2 with cisplatin at 80 mg/m 2 plus growth factor support on arm A, and docetaxel was administered at 100 mg/m 2 on day 8 with gemcitabine at 1100 mg/m 2 on days 1 and 8, also with growth factor support, on arm B. Overall response rates were virtually identical at 32% in arm A and 33% in arm B, and one-year and median survival rates did not differ between the two groups. However, the docetaxel/gemcitabine combination was significantly more active than the cisplatin-based regimen in adenocarcinomas (51% vs. 20%; P = 0.003), while the cisplatin-based regimen (arm A) was significantly more active in non-adenocarcinomas (38% vs. 23%; P -0.02). Furthermore, the toxicity profile for the regimen without cisplatin was favorable with significantly less nausea, neuropathy, and diarrhea [27] .
Second-line treatment
Docetaxel has been the only compound to date to demonstrate significant activity in the second-line therapy of non-small-cell lung cancer [20] [21] [22] [23] . In the original trial of docetaxel as a second-line agent, Fossella et al. gave 100 mg/m 2 to patients at The University of Texas M.D. Anderson Cancer Center for whom frontline cisplatin-based chemotherapy had failed. Eligibility criteria included Zubrod performance status of 0-2, adequate hematologic, serologic, and hepatic function, and documented failure of one prior platinum-based regimen described as a best response of stable disease vs. progressive disease to prior therapy. In a surprising finding, Fossella et al. demonstrated a response rate of 22% in this patient population with a median survival time of 9.1 months and a one-year survival rate of 40%. In fact, this data was markedly superior when compared with that of contemporary controls at M.D. Anderson for whom prior platinum-based chemotherapy had failed and who were well matched in age, stage, gender, prior chemotherapy, and response to prior chemotherapy. Those patients were treated on a variety of different phase 1 trials at M.D. Anderson Cancer Center. This comparison of contemporary controls yielded a survival advantage between the patients who received docetaxel and the patients who received treatment on a variety of phase I trials. The median survival time was 9.1 months for the patients who received docetaxel and four months for patients who received other treatment. The one year survival rate was also superior at 40% vs. 16% in favor of the patients who received docetaxel (P = 0.003).
Based on this data and confirmatory data from other investigators, two randomized trials of docetaxel in the second-line therapy of non-small-cell lung cancer were launched. Shepherd et al. [24] formulated a multi-institutional trial of docetaxel (100 mg/m 2 by one-hour IV infusion with premedication with dexamethasone) vs. best supportive care in patients for whom at least one initial regimen of cisplatin or carboplatin-based chemotherapy had failed. After the initial 100 patients were randomized and significant toxic effects were seen at the docetaxel dose of 100 mg/m 2 , the protocol was amended and the dose lowered to 75 mg/m 2 . The primary endpoint of the trial was survival with secondary endpoints being response rates, time to disease progression, safety/toxicity, quality of life, and clinical benefit assessments. Patients for whom at least one prior platinum-based chemotherapy regimen had failed, who had acceptable peripheral neuropathy (grade < 2), no prior taxane treatment, and adequate hematologic and biochemical parameters were eligible. Only patients whose ECOG performance status was 0 to 2 and who were 21 days out from their last dose of chemotherapy were treated. Approximately 200 patients were randomly assigned to receive either docetaxel or best supportive care. There was stratification by performance status and best response to prior therapy. Response rates on both docetaxel arms were disappointing; the cumulative response rate was only 6%. Patients who received docetaxel, particularly the 75 mg/m 2 dose, remained disease free of progression for significantly longer than those who received (12.3 weeks vs. 7.0 weeks; P = 0.004). Overall survival time for the patients who received docetaxel and was superior to the overall survival times of the patient who received supportive care (7.6 months vs. 4.8 months; P -0.047). Median survival time were 7.5 months for patients who received docetaxel and 4.6 months for patients who received best supportive care (P = 0.010). The one-year survival rate was similarly superior at 37% vs. 12% (P = 0.003) ( Table 2) . Clinical benefit and quality of life were greater for patients who received docetaxel, and their use of palliative radiation and narcotic analgesics was less frequent than that of patients who received best supportive care.
Fossella et al. carried out a more ambitious randomized phase III trial [25] to compare docetaxel at 100 mg/m 2 every 21 days, docetaxel at 75 mg/m 2 also every 21 days, and a physician's choice of vinorelbine at 25 mg/m 2 /weekly or ifosfamide at 2 g/m 2 /Dl-3 every 21 days. Three hundred seventy-three patients took part in the trial. Docetaxel at 75 mg/m 2 produced the best survival rates of the three arms at one year (32% vs. 19% for vinorelbine or ifosfamide; P = 0.025). Interestingly, the median survival rates among the three arms were not significantly different (Table 2 ).
In our follow-up analysis, we censored the data pertaining to patients who received subsequent taxanebased therapy and found that docetaxel at both dose levels produced one-year survival rates of 32% vs. a oneyear survival rate of 10% for recipients of vinorelbine/ ifosfamide (P -< 0.001 in favor of docetaxel). Furthermore, in this trial as in the Shepherd trial, symptom palliation measures were fewest, and overall quality of life was greatest among the patients who received docetaxel at 75 mg/m 2 ( Table 2 ). In spite of some evidence that gemcitabine [26] may have some activity in patients whose disease had previously responded or was stable after front-line chemotherapy, docetaxel remains the only agent that has demonstrated activity in the second-line setting including among patients whose disease progressed during or after front-line chemotherapy. Interestingly, the Fossella et al. [25] trial allowed patients who had received paclitaxel earlier to be enrolled on study; prior exposure to paclitaxel did not predict likely response to docetaxel.
Molecuarly targeted therapeutic approaches
Multiple novel agents are being tested for the treatment of non-small-cell lung cancer (see Table 3 for a partial list). Among these, farnesyl transferase inhibitors are among the furthest along in development [28] . Several trials combining farnesyl transferase inhibitors with taxanes have recently been launched. Preclinical data from Moasser et al. indicating that farnesyl transferase inhibitors are capable of overcoming mechanisms of resistance to taxoids through upregulation of bax and downregulation of bcl-2 as well as enhancement of taxane-induced cell cycle arrest provides the rationale for these studies [29] .
In a phase I trial of SCH66336 plus paclitaxel in patients with solid tumors, most of whom had received Table 3 Novel agents in clinical trials for NSCLC.
• Signal transduction inhibitors' -Tyrosine kinase inhibitors (e.g., ZD1839), -Farnesyl transferase inhibitors (e.g., SCH66336. Rl 15777, BMS224662).
• Novel retinoids: -RXR-specific (bexarotene); -RAR-specific (hposomal ATRA).
• Antiangiogeneic agents: -Interferons (a-IFN, PEG-interferon); -Fungal products (TNP-470); -Endostatin/angiostatin.
extensive prior treatment, we saw a surprisingly high number of patients whose disease showed a clinical response. There were 21 patients whose progress could be evaluated. In 8 of the 21 cases, the disease responded to treatment, while in only 5 cases, there was disease progression by cycle 3 [30] . Preliminary data seem to indicate enhancement of paclitaxel activity without impact on paclitaxel pharmacokinetics by adding SCH66336, a non-peptidominetic farnesyl transferase inhibitor manufactured by Schering Plough Pharmaceuticals. Trials of docetaxel with SCH66336 (Schering Plough) and Rl 15777 (Janssen Pharmaceuticals) are planned such that docetaxel can be administered either weekly or every three weeks in combination with a daily oral farnesyl transferase inhibitor.
Other new paradigms are under exploration for the treatment of human cancer by manipulating other specific aspects of the biology of NSCLC. There is increasing evidence that Epidermal Growth Factor Receptor (EGFR) is over expressed in an extensive range of human cancers, including non-small-cell lung cancer [31] . Importantly this has been correlated with a poor prognosis in NSCLC [31] .
Extensive clinical experience now exists with ZD1839, a novel tyrosine kinase inhibitor, which binds to a location close to the ATP binding site in the intracellular kinase domain of the epidermal growth factor receptor (EGFR). Activation causes EGFR itself and a number of cellular substrates to become phosphorylated on tyrosine residues, thereby causing dysregulated growth inhibiting cellular differentiation. ZD1839 is a potent, relatively specific inhibitor of EGFR and its use in epithelialy derived EGFR expressing and over-expressing NSCLC has now been tested both preclinically [32] and clinically [33] .
Baselga et al. carried out a phase I trial assaying the efficacy of ZD1839 in approximately 150 patients with a variety of different solid tumors [33] . Importantly, they saw durable tumor regressions in patients with NSCLC who had been extensively previously treated, including patients who had failed up to three prior chemotherapy regiments. Many of these responses were quite durable in nature, leading to further investigation of this compound in NSCLC in phase III front-line combination trials as well as third-line single agent trials.
DeVore et al. conducted a randomized Phase III trial of carboplatin and paclitaxel, either alone or in combination with two dose levels of a recombinant human monoclonal antibody to the vascular endothethial growth factor (VEGF) [34] . The combination of this monoclonal antibody (rhuMab VEGF), at high doses (15 mg/m 2 /weekly), with paclitaxel and carboplatin had a superior time to progression compared to the cytotoxic combination alone. Concern over a number of patients on the rhuMab VEGF arms who had life-threatening, and even fatal hemorrhages, particularly at high doses, has tempered the enthusiasm for further developing this agent in NSCLC, where a substantial number of patients have asymptomatic brain metastases.
Conclusion
Five years have passed since a meta-analysis of the role of chemotherapy in the treatment of non-small-cell lung cancer indicated that a modest but real survival benefit was achievable [35] . In that time modest progress with new cytotoxic agents and enhanced excitement utilizing targeted molecular therapeutic agents has led to a pervasive optimism that significant progress in survival of NSCLC patients is achievable.
In summary, substantial progress has been made in the treatment of non-small-cell lung cancer with frontline therapy using novel cytotoxics yielding a median survival time of eight to nine months and a one-year survival rate of 33% to 39%. In the second-line setting, 75 mg/m 2 docetaxel has shown surprising activity and efficacy. Finally, novel agents including signal transduction inhibitors such as the farnesyl transferase inhibitors may enhance the usefulness of the newer and more potent cytotoxics that were developed over the last decade to combat non-small-cell lung cancer.
